SPATA2 and diffuse large B-cell lymphoma of the central nervous system: The success of this trial was attributed to CD274/PDCD1LG2 gains, amplifications, and translocations that are commonly seen in patients with primary CNS DLBCL (60%) and primary testicular DLBCL (60%) and further emphasizes the importance of these PD-1 ligands in predicting PD-1 antibody treatment success (Chapuy et al., 2016; Nayak et al., 2017).